

Thursday, November 12th, 2015
7:15 a.m. to 8:15 a.m.
Cannon Health Building
Room 125

Board Members Present:

Jay Aldus, D.D.S

Ben Berrett, Pharm.D.

Neal Catalano, Pharm.D

Holly Gurgle, Pharm.D.

Steve Lore, M.D.

Keith Tolman, M.D.

Jennifer Brinton, M.D., Board Chair

Susan Siegfried, M.D.

Kumar Shah, M.Sc., P.Eng.

Katherine Smith, Pharm.D.

Michael Symond, M.D.

Board Members Excused:

N/A

Dept. of Health/Div. of Health Care Financing Staff Present:

Chad Hope, PharmD

Bryan Larson, PharmD

Merelynn Berrett, R.N

Heather Santacruz, R.N.

Alyssa Pitts, R.N.

Other Individuals Present:

Gary Oderda, University of Utah

Joanita Lake, University of Utah

Eliot Brinton, Utah Lipid Center

Cody Ball, Select Heath

Mindy Peterson, Healthy U

Laura Britton, Healthy U

Greg Gittus, Alkermes

Paul Skodny, Amgen

Charissa Anne, Johnson & Johnson

Chris Desimone, Agerion

Lori Howarth, Bayer

Meeting conducted by: Bryan Larson, Pharm.D.

1. **Welcome & Housekeeping:** Bryan Larson opened the meeting in place of Robyn Seely who was out of town. He reminded everyone that it is important that they all sign in when they arrive.
2. **Review and Approval of October Minutes:** Jennifer Brinton made a motion to approve the minutes from October. All in favor.
3. **Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors:** Jennifer Brinton reminded everyone that this is a continuation of last month's topic. Bryan Larson went over the proposed PA criteria that was discussed at the last meeting.

4. **Public Comments:** Joanita Lake discussed restrictions to this class.
Eliot Brinton discussed what a patient must do before they can be prescribed a medication from this class.

5. **Board Discussion**

- a. Statin intolerability was discussed and how we could define that in the PA criteria.
- b. It was discussed to make this a restricted class where a patient would have to see a lipid specialist to have a medication from this class prescribed. In rural areas where a specialist may not be nearby, Medicaid will pay for transportation.
- c. Eliot Brinton, a lipid specialist, said that people should not necessarily have to physically go see the specialist, but instead could have a phone consultation.
- d. Chad Hope stated that we had a hard time defining what a pain specialist was in the past, so it would be very important to define what exactly a lipid specialist is.
- e. Keith Tolman disagreed with the idea of making people go to a specialist for these medications. He believes that doing so would be like going back in time in healthcare to days when only cardiologists were allowed to hold a stethoscope. He stated that if we make good PA criteria, it should be fine to allow any doctor to prescribe them.
- f. Jennifer Brinton made a note of the three changes that need to be made: Clarify what statin intolerance is, add a consultation requirement, and add a point about undefined risk.
- g. Bryan Larson went over the proposed new PA criteria and the new definitions.
- h. Steve Lore made a motion to approve the new PA criteria. Neal Catalano seconded.
All in favor

The new criteria is: Failure on a statin at maximum approved dose to establish statin insufficiency, or minimum dose to establish patient intolerability. Intolerance is defined as failing at least 2 statins, at least one at the lowest approved dose.

For very high risk patients: $LDL \geq 100$ or non HDL ≥ 130 .

For high risk: Heterozygous FH, or Type 2 Diabetes, or two major risk factors as defined by current guidelines

For undefined risk, $LDL \geq 160$ or non HDL ≥ 190 with one risk factor.

Medication should be prescribed by, or in consultation with, an ABCL (or equivalent) certified lipid specialist.

Steve Lore made a motion. Neal Catalano seconded. All in favor.

6. **Meeting Adjourned**

Michael Symond motioned to close the meeting. Steve Lore seconded. All in favor.

7. Next meeting is scheduled for December 10th, 2015. Topical Lidocaine products will be discussed.